Search results
Predicts malignancy risk in solitary lung nodules on chest x-ray. INSTRUCTIONS Do not use in patients with prior lung cancer diagnosis or with history of extrathoracic cancer diagnosed within 5 years of nodule presentation.
1 lip 2019 · The current study examines the efficacy, safety, and tolerability of ASP8273 versus erlotinib or gefitinib in patients with non-small-cell lung cancer (NSCLC) with activating EGFR mutations not previously treated with an EGFR inhibitor.
14 gru 2017 · ASP8273 demonstrated antitumor activity in patients with EGFR-mutant lung cancers after prior treatment with EGFR TKIs. This study identified the ASP8273 RP2D to be 300 mg daily based on pharmacokinetics, pharmacodynamics, safety, and antitumor activity; the MTD was not established.
15 gru 2017 · ASP8273 is a third-generation EGFR TKI with antitumor activity in preclinical models of EGFR-mutant lung cancer that targets mutant EGFR, including EGFR T790M. Experimental Design: In this multicohort, phase I study ( NCT02113813 ), escalating doses of ASP8273 (25-500 mg) were administered once daily to non-small cell lung cancer (NSCLC ...
7 sty 2022 · A blood-based biomarker panel in combination with PLCO m2012 significantly improves lung cancer risk assessment for lung cancer screening.
the process to select and assess the individual cases for entry into the programme, the LHC and the risk assessment for lung cancer. The clinician can be a doctor, nurse or other professional with the appropriate clinical authority and accountability, from either the local primary or secondary care team. They will continually oversee and monitor
Individualized Lung Cancer Risks and Screening Benefit Calculator. DCEG investigators developed models to estimate a current or former smoker’s risk of developing lung cancer and their gain in life-expectancy from lung cancer screening, freely available online at ScreenLC.com. These models included:
